Although programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) have been approved as clinical biomarkers of response to ICIs, the assessment is still challenging, due to inadequate sample, spatial and temporal heterogeneity [9]. This evidence concerns the gene CD274 and neoplasm.